We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 4,080

Network interference - a legal guide to the commercial risks and rewards of the social media phenomenon
  • Reed Smith LLP
  • European Union, Global, United Kingdom, USA
  • April 22 2014

Social media is a revolution in the way in which corporations communicate with consumers. This White Paper will help you to maximise the huge


FDA files brief regarding off-label promotion in Amarin Pharma lawsuit
  • Reed Smith LLP
  • USA
  • June 27 2015

As we mentioned in our prior post, the Amarin Pharma, Inc. v. United States Food and Drug Administration lawsuit pending in the Southern District of


Texas hospital CFO pleads guilty to making a HITECH Act false statement
  • Reed Smith LLP
  • USA
  • June 25 2015

The HITECH Actincluding the HITECH Final Rule’s provisions about HIPAA, data privacy, security, and breach notificationis an issue we have covered


CMS proposed 2016 Medicare payment rules in the pipeline
  • Reed Smith LLP
  • USA
  • June 30 2015

CMS recently sent several major proposed Medicare CY 2016 payment rules to the White House Office of Management and Budget (OMB) for regulatory


FDA sued by drug manufacturer over constitutional right to discuss off-label uses
  • Reed Smith LLP
  • USA
  • June 18 2015

The FDA has long sought to ban manufacturers from promoting off-label uses of approved drugs and medical devices. In taking the position that


CMS releases CY 2016 ESRD PPS proposed rule
  • Reed Smith LLP
  • USA
  • June 30 2015

On June 26, 2015, the Centers for Medicare & Medicaid Services (CMS) released its proposed rule to update the Medicare end-stage renal disease (ESRD


Amarin Pharma v. FDA more briefs filed regarding off-label promotion and the First Amendment
  • Reed Smith LLP
  • USA
  • July 3 2015

Our prior posts looked at the Amarin Pharma, Inc. v. United States Food and Drug Administration lawsuit, which raises issues regarding the First


CMS revises expands ACO “Investment Model” opportunities
  • Reed Smith LLP
  • USA
  • June 29 2015

As previously reported, CMS announced a Medicare Shared Savings ProgramAccountable Care Organization (ACO) “Investment Model” last fall to better


MDL court agrees Tincher doesn’t change Pennsylvania drugdevice law
  • Reed Smith LLP
  • USA
  • June 18 2015

Several months ago we responded with some disdain to recent plaintiff-side arguments we had seen claiming that the strict liability decision in


No prescription for consumer protection
  • Reed Smith LLP
  • USA
  • June 25 2015

Allowing plaintiffs to pursue claims under consumer protection statutes in prescription medical product liability litigation is trying to pound a